New Antibody Gets Fast-Track for Childhood Neuroblastoma
Families of children with newly diagnosed high-risk neuroblastoma may eventually see a new first-line option, though it is not yet approved.
Updated on Nov. 16, 2026 in Cancer

The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to daretabart, an investigational anti-GD2 antibody, for first-line treatment of newly diagnosed high-risk neuroblastoma in children, used in combination with induction chemotherapy. The drug is not approved by any regulator, so the designation speeds development rather than making it available to families now.
Why it matters
Neuroblastoma is a rare childhood cancer, and high-risk cases have long been difficult to treat, so a designation that prioritizes a new first-line option matters to families and clinicians facing these diagnoses. It arrives on the strength of early single-arm data, which means it signals promise rather than proven benefit.
The designation rests on a Phase II, open-label, single-arm trial in 64 children with newly diagnosed high-risk neuroblastoma, conducted at one centre and published in the Journal of Clinical Oncology in December 2021. Three-year event-free survival was 73.7% and three-year overall survival was 86.0%, but without a randomized comparison group the effect relative to existing treatment cannot be confirmed.
The players
Renaissance Pharma Limited
An Essential Pharma company focused on development-stage assets, including daretabart, which is being developed under an exclusive license from St. Jude Children's Research Hospital.
U.S. Food and Drug Administration
The U.S. regulator that grants expedited pathways such as Breakthrough Therapy Designation to investigational medicines with evidence of substantial improvement over existing therapies.
The details
Daretabart is a humanised monoclonal antibody that targets GD2, a molecule found on the surface of neuroblastoma cells, and is given alongside induction chemotherapy. In the Phase II trial, the antibody infusion caused Grade 3 or 4 side effects in a minority of treatment cycles, including pain in 10% of 379 cycles, hypoxia in 6%, infusion-related reactions in 4%, hypotension in 3% and cough in 1%. These toxicities are the main safety signals the next stage of study will need to characterize.
Timeline
December 2021: Phase II daretabart data were published in the Journal of Clinical Oncology.
November 16, 2026: The FDA's Breakthrough Therapy Designation for daretabart was announced.
Health Landscape
The FDA's Breakthrough Therapy program is designed to speed review of investigational medicines that may substantially improve on existing treatment, and this designation applies it to first-line high-risk neuroblastoma, a setting where survival has plateaued near 50%. It follows the broader pattern of antibody-based therapies that target tumor-specific surface markers in childhood cancers.
If you or a child in your care has been diagnosed with high-risk neuroblastoma, this designation is a signal of research progress rather than a treatment you can access today, so it is worth asking your oncologist whether clinical trials for daretabart or similar therapies may be an option. Families should also be aware that antibody infusions can cause pain and infusion reactions, which care teams monitor closely.
The takeaway
Breakthrough designation reflects encouraging early data, not an approved therapy, so the strongest next signal will come from larger, controlled studies. Anyone with questions about neuroblastoma treatment options should raise them with a pediatric oncology team.
Further reading
For more background on the treatments being tested against childhood tumors, explore our Cancer coverage.


